Which statement is true about the shared adverse effects of Deferiprone and Deferasirox?

Which statement is true about the shared adverse effects of Deferiprone and Deferasirox?

• A. GI side effects and elevated liver enzymes
• B. Nephrotoxicity and ototoxicity
• C. Hyperglycemia and hyponatremia
• D. Hypokalemia and arrhythmias

Answer: (A)

Both deferiprone and deferasirox are taken orally and commonly cause irritation of the gastrointestinal tract and some level of liver stress. This means patients often experience GI symptoms such as nausea or abdominal discomfort, and laboratory tests can show elevated liver enzymes (AST/ALT), reflecting hepatocellular impact. Clinically, this shared pattern underscores the need to monitor liver function tests during therapy with either drug and to counsel patients about GI tolerance. The other potential adverse effects listed are not shared features of these two chelators. For example, the major hematologic risk with deferiprone is neutropenia/agranulocytosis, which isn’t a characteristic shared with deferasirox, and deferasirox has its own notable risks, including potential nephrotoxicity and other organ effects not typically seen with deferiprone. Hyperglycemia, hyponatremia, hypokalemia, and arrhythmias are not typical shared toxicities of these agents.

Both deferiprone and deferasirox are taken orally and commonly cause irritation of the gastrointestinal tract and some level of liver stress. This means patients often experience GI symptoms such as nausea or abdominal discomfort, and laboratory tests can show elevated liver enzymes (AST/ALT), reflecting hepatocellular impact. Clinically, this shared pattern underscores the need to monitor liver function tests during therapy with either drug and to counsel patients about GI tolerance.

The other potential adverse effects listed are not shared features of these two chelators. For example, the major hematologic risk with deferiprone is neutropenia/agranulocytosis, which isn’t a characteristic shared with deferasirox, and deferasirox has its own notable risks, including potential nephrotoxicity and other organ effects not typically seen with deferiprone. Hyperglycemia, hyponatremia, hypokalemia, and arrhythmias are not typical shared toxicities of these agents.